💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Tarsons Products Limited is an India-based labware company. The Company is engaged in designing, development, manufacturing and marketing of consumables, reusables and others including benchtop equipment, used in various laboratories across research organizations, academia…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak, stagnant business, priced for perfection — but flagged on governance.
Tarsons Products is scored on the general / industrial framework. It keeps a thin 3.2% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 8.27× reported profit. Free cash flow is worth about -0.7% of its market value.
Over the last 3 years revenue compounded at 13%/yr and profit at -48%/yr. Book value has grown 9%/yr. Return on equity is a weak 2.3%. In the latest quarter profit fell 134% versus the prior quarter.
At 118× earnings, the stock sits at the 97th percentile of its own 4.6-year range — the expensive end of where it has historically traded. Today's price already implies ~37%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises a red flag: 110% of pre-tax profit is other income, not operations.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 151.82 | 38.38 | worse |
| P/B | 2.66 | 2.02 | worse |
| EV/EBITDA | 14.23 | 10.1 | worse |
| ROE | 2.26 | 8.48 | worse |
| ROCE | 4.09 | 7.07 | worse |
| ROA | 0.94 | — | — |
| Quick Ratio | 0.51 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
13% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Revenue is outpacing profit (13% vs -48%) — costs are rising faster than the top line. The latest year saw a -52% swing — check if it's a one-off or structural.
Operating margin has compressed from 44% to 5% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line. Margins have declined for 3 consecutive years — watch for a structural cost problem.
ROE at 2% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 18pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -48% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 8.3× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 9% QoQ — could be seasonality or a genuine slowdown. Run-rate stepping up — recent quarters average 9% above earlier ones.
1 of 4 quarters loss-making — quarterly profitability is uneven. Profit fell 134% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (3% → -1%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 4.6y median.
Promoters at 47.3% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.